Sulfosuccinimidyl oleate sodium [1212012-37-7]
Referência NB-64-04567-25mg
Tamanho : 25mg
Marca : Neo Biotech
Datasheet (EN)Sulfosuccinimidyl oleate sodium
Alias Sulfo-N-succinimidyl oleate sodium
Sulfosuccinimidyl oleate sodium is a long-chain fatty acid that inhibits fatty acid transport into cells and is a potent and irreversible inhibitor of the mitochondrial respiratory chain and has anti-inflammatory properties without causing cytotoxic effects.
Product Introduction
Bioactivity
Chemical Properties
| Description | Sulfosuccinimidyl oleate sodium is a long-chain fatty acid that inhibits fatty acid transport into cells and is a potent and irreversible inhibitor of the mitochondrial respiratory chain and has anti-inflammatory properties without causing cytotoxic effects. |
| Targets&IC50 | mitoCHO cellsndrial respiratory chain:4 μM |
| In vitro | METHODS: BV2 cells were treated with Sulfosuccinimidyl oleate sodium (50μM) and exposed to 100 ng/ml LPS and 5 ng/ml IFNγ. The mRNA expression levels of IL-6, NOS2, Nrf2 and HO-1 were detected by qRT-PCR; WB detects the expression of NOS2, COX-2, HO-1, p-p38, t-p38 and β-actin in cells. RESULTS Combined treatment with Sulfosuccinimidyl oleate sodium blocked the increase in the expression levels of IL-6 and NOS2; co-treatment with SSO allowed LPS + IFNγ to reduce the Nrf2 expression level back to the basal level; combined treatment with Sulfosuccinimidyl oleate sodium significantly reduced the expression level of Nrf2. Expression of NOS2 and COX-2 in BV2 cells induced by LPS + IFNγ; Sulfosuccinimidyl oleate sodium alone increased the basal protein level of HO-1, but did not change the level of HO-1 induced by LPS + IFNγ. [1] |
| In vivo | METHODS: Sulfosuccinimidyl oleate sodium (50 mg/kg, oral) was treated in pMCAo mice and its therapeutic effect was tested; mice were analyzed for ischemia-induced cerebral microgliosis by immunohistochemical staining against Iba-1 3 days after stroke. RESULTS Sulfosuccinimidyl oleate sodium significantly reduced the size of cortical ischemic infarcts, and significantly upregulated microgliosis was detected in the peri-ischemic area of sulfosuccinimidyl oleate sodium-treated mice 3 days after stroke. A significant decrease in the degree of Iba-1 immunoreactivity was observed in the peri-ischemic area. [1] |
| Synonyms | Sulfo-N-succinimidyl oleate sodium |
| Molecular Weight | 481.58 |
| Formula | C22H36NNaO7S |
| Cas No. | 1212012-37-7 |
| Smiles | CCCCCCCC/C=C\CCCCCCCC(ON1C(C(S(=O)([O-])=O)CC1=O)=O)=O.[Na+] |
| Color | White |
| Appearance | Solid |
Storage & Solubility Information
| Storage | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 70 mg/mL (145.35 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.15 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||